RETATRUTIDE (LY3437943)

Research Use Only (RUO)

Product Category: Investigational Research Compound
Research Classification: Synthetic Peptide
Intended Application: Laboratory & Scientific Research
Human Use: Not for human use
Veterinary Use: Not for veterinary use

---

1. Product Overview

Retatrutide, also identified by the development code LY3437943, is an investigational synthetic peptide being studied for its biological activity across multiple metabolic pathways. Developed by Eli Lilly and Company, retatrutide is described as a triple hormone receptor agonist because it activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

Its combined receptor activity makes retatrutide a subject of ongoing scientific research into metabolic regulation, energy balance, glucose metabolism, and related physiological processes.

2. Research Use Only (RUO) Designation

This material is designated Research Use Only (RUO) and is intended exclusively for qualified laboratory and scientific research.

It is not intended for human consumption, self-administration, veterinary use, diagnosis, treatment, prevention of disease, or use as a pharmaceutical or dietary supplement. The RUO designation distinguishes research material from approved medicinal products and should not be interpreted as evidence of regulatory approval or clinical suitability.

3. Retatrutide Mechanism of Action

Retatrutide is being investigated for activity at three receptor pathways: GIP, GLP-1, and glucagon. This triple-agonist mechanism is of particular scientific interest because these pathways have distinct but potentially complementary physiological effects.

GIP and GLP-1 receptor activity is associated with incretin signaling and glucose-dependent metabolic responses, while glucagon receptor activity is being investigated in relation to energy expenditure and hepatic metabolism.

4. Current Research Areas

Retatrutide is being investigated in a broad clinical development program. Research has examined its potential effects in areas including obesity and overweight, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.

These investigations are designed to evaluate the compound’s efficacy, safety, pharmacological characteristics, and potential clinical applications.

5. Scientific and Metabolic Research

Studying the GIP, GLP-1, and glucagon pathways together may help researchers better understand interactions between appetite regulation, glucose homeostasis, lipid metabolism, and energy balance.

Research into these mechanisms may contribute to a broader understanding of metabolic physiology and potential future therapeutic approaches. Findings should be interpreted within the context of the individual research protocol and available scientific evidence.

6. Clinical Research Overview

Clinical research has reported effects on body weight and metabolic measures in several study populations. Lilly has reported positive Phase 3 results from the TRIUMPH program, including substantial reductions in body weight among participants with obesity or overweight.

These findings remain part of the investigational development program and should not be interpreted as evidence that research material supplied outside an authorized clinical trial is suitable for therapeutic use.

7. Product Specifications & Classification

Specification	Information
Product	Retatrutide (LY3437943)
Classification	Investigational research compound
Material Type	Synthetic peptide
Intended Application	Laboratory & scientific research
Designation	Research Use Only (RUO)
Human Use	Not for human use
Veterinary Use	Not for veterinary use
Therapeutic Claims	None
Regulatory Status	Investigational

8. Research Material & Documentation

Researchers should review the documentation supplied with the specific research material, including the applicable certificate of analysis, analytical specifications, identity and purity information, storage requirements, lot or batch identification, and available testing documentation.

Experimental materials should be evaluated according to the requirements of the relevant laboratory, institution, and research protocol.

9. Regulatory Status

Retatrutide remains an investigational molecule and has not been approved as a general-use medicine by the U.S. FDA or other regulatory authorities. Lilly states that retatrutide is currently being evaluated in Phase 3 clinical trials.

Regulatory status may change as clinical development and regulatory review progress. Researchers should consult current official regulatory and manufacturer information when assessing the status of the compound.

10. Important Research Use Only Notice

This product description is provided solely for scientific identification and research purposes.

The Research Use Only designation does not indicate that the material is sterile, clinically validated, approved for administration, or suitable for human or animal use. No therapeutic, diagnostic, preventive, or performance-enhancing claims are made or implied.

Researchers are responsible for ensuring that any use of research material complies with applicable laws, institutional policies, laboratory procedures, and relevant safety requirements.

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

11. Alternative Retatrutide Research Quantities

Additional retatrutide research quantities may be available for researchers requiring different amounts of material for laboratory applications. Please select from the available research-use-only options below. Each option is supplied solely for qualified scientific research and is not intended for human or veterinary use.

Retatrutide (20mg)

Retatrutide (10mg)